+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Vaccines Market by Type and Geography - Forecast and Analysis 2020-2024 - Product Image

Vaccines Market by Type and Geography - Forecast and Analysis 2020-2024

  • ID: 4855486
  • Report
  • November 2019
  • Region: Global
  • 160 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Bavarian Nordic AS
  • CSL Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Novavax Inc.
  • Pfizer Inc.
  • MORE
Global Vaccines Market: About this market
The vaccines market analysis considers sales from both prophylactic vaccines and therapeutic vaccine types. Our analysis also considers the sales of vaccines in Asia, Europe, North America, and ROW. In 2019, the prophylactic vaccines segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high safety and efficacy will play a significant role in the prophylactic vaccines segment to maintain its market position. Also, our global vaccines market report looks at factors such as increased funding for vaccine development and new vaccine launches, approval of vaccines and strong pipeline, and increasing use of adjuvants in vaccines. However, high costs of vaccine research, development, and manufacturing, product recalls, and safety concerns may hamper the growth of the vaccines industry over the forecast period.

Global Vaccines Market: Overview

Increasing the use of adjuvants in vaccines
With the increasing use of vaccines to treat and prevent life-threatening diseases, vendors are focusing on strategies for the development of effective new vaccines and usage of suitable adjuvants. They work by improving the humoral and cell-mediated immune response to vaccine antigens. The rise of the use of adjuvants, such as immunologic adjuvants, in new vaccines has increased to combat emerging new pathogens and re-emerging old pathogens. The demand for such vaccines is also high because of their long-lasting protective immune response. This will lead to the expansion of the global vaccines market at a CAGR of almost 7% during the forecast period.

Development of nanoparticle vaccines
The nanoparticle-based vaccines have higher immunization and targeted delivery attributes. This has led the vendors to invest in R&D of nanoparticle vaccines due to the ongoing research to develop vaccines against specific diseases. For instance, prophylactic vaccines are associated with the risk of regaining their pathogenicity under certain immunocompromised conditions. This limitation can be overcome by using nanoparticle vaccines. Such development is expected to have a positive impact on the overall market growth.

Competitive Landscape
With the presence of a few major players, the global vaccines market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading vaccines manufacturers, that include Bavarian Nordic AS, CSL Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Novavax Inc., Pfizer Inc., and Sanofi

Also, the vaccine market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bavarian Nordic AS
  • CSL Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Novavax Inc.
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Parent market
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Prophylactic vaccines - Market size and forecast 2019-2024
  • Therapeutic vaccines - Market size and forecast 2019-2024
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • R&D of novel vaccines
  • Development of nanoparticle vaccines
  • Advancement in vaccine delivery system
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bavarian Nordic AS
  • CSL Ltd.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline Plc
  • Inovio Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Novavax Inc.
  • Pfizer Inc.
  • Sanofi
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2019
Exhibit 18: Type - Market share 2019-2024 (%)
Exhibit 19: Comparison by type
Exhibit 20: Prophylactic vaccines - Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Prophylactic vaccines - Year-over-year growth 2020-2024 (%)
Exhibit 22: Therapeutic vaccines - Market size and forecast 2019-2024 ($ millions)
Exhibit 23: Therapeutic vaccines - Year-over-year growth 2020-2024 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2019-2024 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2019-2024 ($ millions)
Exhibit 29: North America - Year-over-year growth 2020-2024 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2019-2024 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2020-2024 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2019-2024 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2020-2024 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2019-2024 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2020-2024 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Bavarian Nordic AS - Vendor overview
Exhibit 49: Bavarian Nordic AS - Business segments
Exhibit 50: Bavarian Nordic AS - Organizational developments
Exhibit 51: Bavarian Nordic AS - Geographic focus
Exhibit 52: Bavarian Nordic AS - Key offerings
Exhibit 53: Bavarian Nordic AS - Key customers
Exhibit 54: CSL Ltd. - Vendor overview
Exhibit 55: CSL Ltd. - Business segments
Exhibit 56: CSL Ltd. - Organizational developments
Exhibit 57: CSL Ltd. - Geographic focus
Exhibit 58: CSL Ltd. - Segment focus
Exhibit 59: CSL Ltd. - Key offerings
Exhibit 60: CSL Ltd. - Key customers
Exhibit 61: Emergent BioSolutions Inc. - Vendor overview
Exhibit 62: Emergent BioSolutions Inc. - Business segments
Exhibit 63: Emergent BioSolutions Inc. - Organizational developments
Exhibit 64: Emergent BioSolutions Inc. - Key offerings
Exhibit 65: Emergent BioSolutions Inc. - Key customers
Exhibit 66: GlaxoSmithKline Plc - Vendor overview
Exhibit 67: GlaxoSmithKline Plc - Business segments
Exhibit 68: GlaxoSmithKline Plc - Organizational developments
Exhibit 69: GlaxoSmithKline Plc - Geographic focus
Exhibit 70: GlaxoSmithKline Plc - Segment focus
Exhibit 71: GlaxoSmithKline Plc - Key offerings
Exhibit 72: GlaxoSmithKline Plc - Key customers
Exhibit 73: Inovio Pharmaceuticals Inc. - Vendor overview
Exhibit 74: Inovio Pharmaceuticals Inc. - Business segments
Exhibit 75: Inovio Pharmaceuticals Inc. - Organizational developments
Exhibit 76: Inovio Pharmaceuticals Inc. - Key offerings
Exhibit 77: Inovio Pharmaceuticals Inc. - Key customers
Exhibit 78: Merck & Co. Inc. - Vendor overview
Exhibit 79: Merck & Co. Inc. - Business segments
Exhibit 80: Merck & Co. Inc. - Organizational developments
Exhibit 81: Merck & Co. Inc. - Geographic focus
Exhibit 82: Merck & Co. Inc. - Segment focus
Exhibit 83: Merck & Co. Inc. - Key offerings
Exhibit 84: Merck & Co. Inc. - Key customers
Exhibit 85: Mitsubishi Tanabe Pharma Corp. - Vendor overview
Exhibit 86: Mitsubishi Tanabe Pharma Corp. - Business segments
Exhibit 87: Mitsubishi Tanabe Pharma Corp. - Organizational developments
Exhibit 88: Mitsubishi Tanabe Pharma Corp. - Geographic focus
Exhibit 89: Mitsubishi Tanabe Pharma Corp. - Key offerings
Exhibit 90: Mitsubishi Tanabe Pharma Corp. - Key customers
Exhibit 91: Novavax Inc. - Vendor overview
Exhibit 92: Novavax Inc. - Business segments
Exhibit 93: Novavax Inc. - Organizational developments
Exhibit 94: Novavax Inc. - Key offerings
Exhibit 95: Novavax Inc. - Key customers
Exhibit 96: Pfizer Inc. - Vendor overview
Exhibit 97: Pfizer Inc. - Business segments
Exhibit 98: Pfizer Inc. - Organizational developments
Exhibit 99: Pfizer Inc. - Geographic focus
Exhibit 100: Pfizer Inc. - Segment focus
Exhibit 101: Pfizer Inc. - Key offerings
Exhibit 102: Pfizer Inc. - Key customers
Exhibit 103: Sanofi - Vendor overview
Exhibit 104: Sanofi - Business segments
Exhibit 105: Sanofi - Organizational developments
Exhibit 106: Sanofi - Geographic focus
Exhibit 107: Sanofi - Segment focus
Exhibit 108: Sanofi - Key offerings
Exhibit 109: Sanofi - Key customers
Exhibit 110: Validation techniques employed for market sizing
Exhibit 111: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Bavarian Nordic AS
  • CSL Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Novavax Inc.
  • Pfizer Inc.
  • MORE
The following companies as the key players in the global vaccines market: Bavarian Nordic AS, CSL Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Novavax Inc., Pfizer Inc., and Sanofi

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of nanoparticle vaccines”

According to the report, one of the major drivers for this market is the Increasing use of adjuvants in vaccines

Further, the report states that one of the major factors hindering the growth of this market is the high costs of vaccines research, development, and manufacturing

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bavarian Nordic AS
  • CSL Ltd.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline Plc
  • Inovio Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Novavax Inc.
  • Pfizer Inc.
  • Sanofi.
Note: Product cover images may vary from those shown
Adroll
adroll